Skip to content
Screener

BioCryst Pharmaceuticals BCRX Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$1.31B+14.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$42.25M
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$572.7M-8.6%
Precigen logo
PrecigenPGEN
$49.26M-34.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$15.19B
Amgen logo
AmgenAMGN
$13.42B+79.2%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.4B+39.2%
Enterprise value$2.65B+40.4%
P/S2.6×-0.5×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300

As of June 30, 2026, the Company had 25 securities with a total estimated fair value of $185,122 in an unrealized loss position. The unrealized losses were primarily attributable to changes in market interest rates and not to deterioration in the credit quality of the issuers. The Company does not have an intent to sell these investments, and it is more likely than not that the investments will be held until recovery of their amortized cost basis. As such, no allowance was recognized.

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's cash, cash equivalents, and marketable securities?
BioCryst Pharmaceuticals (BCRX) reported cash, cash equivalents, and marketable securities of $185.12M in Q2 2026.
How has BioCryst Pharmaceuticals's cash, cash equivalents, and marketable securities changed year-over-year?
BioCryst Pharmaceuticals's cash, cash equivalents, and marketable securities increased by 213.1% year-over-year, from $59.12M to $185.12M.
What does cash, cash equivalents, and marketable securities mean?
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.

Ask your AI about BioCryst Pharmaceuticals's cash, cash equivalents, and marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude